Vaccine News and Research

Latest Vaccine News and Research

Study suggests anti-PF4 antibodies may play a role in the severe multiorgan disease manifestations of COVID-19

Researchers investigated the association between the increased levels of anti-platelet factor 4 antibodies and the clinical complications of COVID-19.

7 Nov 2022

MHRA launches global campaign to improve medical product safety for all

Launched today by the Medicines and Healthcare products Regulatory Agency (the MHRA), the seventh annual #MedSafetyWeek is running until 13 November to encourage widespread public engagement and improve patient safety by reporting suspected side effects associated with medicines and adverse incidents involving medical devices.

6 Nov 2022

Study shows likely SARS-CoV-2 transmission between different rooms of a quarantine hotel

The results of this study, published in the Emerging Infectious Diseases journal, underline the enhanced transmissibility of the Omicron variants of the virus, which takes advantage of small airstreams to jump to new hosts. "Our findings emphasize the importance of ventilation and integrity of building structure in quarantine facilities."

6 Nov 2022

Influenza hospitalizations at highest level in ten years, predicting a severe U.S. flu season

Influenza infection and hospitalization rates continue to increase at an alarmingly fast and early rate this year.

6 Nov 2022

HPV vaccine rates in Utah increase by more than 16% among young men and women, CDC data reveals

When life should have been ripe with possibilities, Mandy Murry instead faced a devastating diagnosis. Murry was diagnosed with cervical cancer when she was 22.

4 Nov 2022

Moderna's COVID-19 vaccine safe and effective in children 6 months to 5 years of age

Moderna's COVID-19 vaccine is safe and effective in children 6 months to 5 years of age, a clinical trial co-led by Vanderbilt University Medical Center vaccine expert C. Buddy Creech, MD, MPH, has found.

4 Nov 2022

Study finds low absolute risk of glomerular disease relapse associated with COVID-19 vaccination

Several reports have described a relapse of certain autoimmune kidney diseases in patients after they've received COVID-19 vaccines, but it's unclear if this association is real or a coincidence.

4 Nov 2022

Vaccinations against COVID-19 lead to higher antibody concentrations in persons with vaccine reactions

After the second and third vaccinations against COVID-19, a significantly higher antibody concentration has been confirmed, while tolerability was good.

4 Nov 2022

Exploring BNT162b2 vaccine effectiveness against COVID-19 among pediatric and adolescent population of Qatar

Researchers evaluated Pfizer-BioNTech’s BNT162b2 messenger ribonucleic acid (mRNA) vaccine effectiveness (VE) against SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) infections among the pediatric and adolescent population of Qatar.

4 Nov 2022

SARS-CoV-2 Omicron's newest subvariant BQ.1.1 shows extraordinary immune evasion potential against vaccine sera

In a new study, researchers pursued immunological evidence of why BQ.1.1 prevalence swiftly increased in areas where Omicron BA.5 was dominant in the United States (US).

4 Nov 2022

Efficacy of booster messenger ribonucleic acid COVID-19 vaccinations against SARS-CoV-2 Omicron variant severity

Researchers estimated the effectiveness of monovalent messenger ribonucleic acid (mRNA) coronavirus disease 2019 (COVID-19) vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant of concern (VOC) infection severity outcomes among adults.

4 Nov 2022

Charles River Laboratories: New Center Expands Cell and Gene Therapy Capabilities

In this interview, Niall Dinwoodie, Executive Director for Gene Therapy for Charles River in Europe discusses the opening of their new HQ Plasmid Center of Excellence at Alderley Park.

From Charles Rivers Laboratories Cell and Gene Therapy 4 Nov 2022

Study evaluates BA.5-bivalent booster against new Omicron sublineages

In a new study, researchers evaluated the efficacy of four doses of parental messenger ribonucleic acid (mRNA) vaccine and a BA.5-bivalent booster against recently emerged Omicron sublineages. Additionally, they determined whether prior infection improved the effect of a booster vaccination.

4 Nov 2022

Specific mutations in the monkeypox virus contribute to its continued infectiousness

Monkeypox has infected more than 77,000 people in more than 100 countries worldwide, and - similar to COVID-19 - mutations have enabled the virus to grow stronger and smarter, evading antiviral drugs and vaccines in its mission to infect more people.

4 Nov 2022

A review of vaccines against the respiratory syncytial virus

This study reviewed the epidemiology, molecular characteristics, populations affected by the virus, and vaccines against RSV.

3 Nov 2022

Political divide and public opinion influence racial disparities in COVID-19 mortality

Researchers at the University of Wisconsin-Madison and the University of California-Los Angeles investigated how political polarization in the United States (US) shaped the time-varying patterns of racial inequality in coronavirus disease 2019 (COVID-19) mortality since the onset of the pandemic.

3 Nov 2022

Bivalent mRNA booster broadens humoral immunity against SARS-CoV-2 Omicron subvariants

Researchers at Emory University, Stanford University, and the National Institute of Allergy and Infectious Diseases evaluated whether bivalent coronavirus disease 2019 (COVID-19) boosters conferred protection against new Omicron subvariants.

2 Nov 2022

RSV and kids: What you need to know

An overview on the prevalence, symptoms, and management of RSV in children.

2 Nov 2022

Nebulized mRNA-encoded antibodies found to protect hamsters against COVID-19

New research describes a novel route of prevention, using messenger ribonucleic acid (mRNA) molecules that encode protective antibodies within the recipient.

2 Nov 2022

Did active monitoring detect potentially elevated risk of health outcomes following BNT162b2 COVID-19 vaccination in the US pediatric population aged 5-17 years?

Researchers used a nearly real-time monitoring framework for early detection of potential safety signals following the administration of the BNT162b2 vaccine in over three million United States children aged five to 17 years.

2 Nov 2022

Vaccine News and Research

Latest Vaccine News and Research

Study suggests anti-PF4 antibodies may play a role in the severe multiorgan disease manifestations of COVID-19

MHRA launches global campaign to improve medical product safety for all

Study shows likely SARS-CoV-2 transmission between different rooms of a quarantine hotel

Influenza hospitalizations at highest level in ten years, predicting a severe U.S. flu season

HPV vaccine rates in Utah increase by more than 16% among young men and women, CDC data reveals

Moderna's COVID-19 vaccine safe and effective in children 6 months to 5 years of age

Study finds low absolute risk of glomerular disease relapse associated with COVID-19 vaccination

Vaccinations against COVID-19 lead to higher antibody concentrations in persons with vaccine reactions

Exploring BNT162b2 vaccine effectiveness against COVID-19 among pediatric and adolescent population of Qatar

SARS-CoV-2 Omicron's newest subvariant BQ.1.1 shows extraordinary immune evasion potential against vaccine sera

Efficacy of booster messenger ribonucleic acid COVID-19 vaccinations against SARS-CoV-2 Omicron variant severity

Charles River Laboratories: New Center Expands Cell and Gene Therapy Capabilities

Study evaluates BA.5-bivalent booster against new Omicron sublineages

Specific mutations in the monkeypox virus contribute to its continued infectiousness

A review of vaccines against the respiratory syncytial virus

Political divide and public opinion influence racial disparities in COVID-19 mortality

Bivalent mRNA booster broadens humoral immunity against SARS-CoV-2 Omicron subvariants

RSV and kids: What you need to know

Nebulized mRNA-encoded antibodies found to protect hamsters against COVID-19

Did active monitoring detect potentially elevated risk of health outcomes following BNT162b2 COVID-19 vaccination in the US pediatric population aged 5-17 years?

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Vaccine News and Research

Latest Vaccine News and Research

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in